Post-Brexit, take control of your supply chain with Wasdell
On January 31st, the United Kingdom officially withdrew its membership of the European Union. There is now a transition period in place until the end of 2020 while the UK and EU negotiate further agreements.
As the EU laws will no longer apply in the UK from January 2021, many UK firms are now concerned about the impact this will have on their supply chains. Ensuring the continued success of the UK pharmaceutical supply chain is a key priority while these negotiations are underway.
We have spent many months implementing a robust contingency plan to ensure Brexit has minimal impact on our operations and our customers’ supply chains. Our recent investment in Ireland provides us with a packaging, storage and distribution facility and the ability to test products for release to the European market. This will allow us to continue enabling the smooth movement of drugs across Europe.
Please do not hesitate to contact us to learn how we can help you navigate Brexit, avoid delays and ensure the effective distribution of your product in the EU market.
Head of Quality & Regulatory Affairs
Follow Wasdell Group on LinkedIn for further updates